Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Total Current Liabilities: 2018-2024

Historic Total Current Liabilities for Whitehawk Therapeutics (WHWK) over the last 7 years, with Dec 2024 value amounting to $17.1 million.

  • Whitehawk Therapeutics' Total Current Liabilities fell 37.72% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 37.72%. This contributed to the annual value of $17.1 million for FY2024, which is 35.31% down from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Total Current Liabilities of $17.1 million as of FY2024, which was down 35.31% from $26.4 million recorded in FY2023.
  • In the past 5 years, Whitehawk Therapeutics' Total Current Liabilities ranged from a high of $30.1 million in FY2020 and a low of $15.3 million during FY2021.
  • In the last 3 years, Whitehawk Therapeutics' Total Current Liabilities had a median value of $18.8 million in 2022 and averaged $20.8 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 801.56% in 2020, then plummeted by 49.19% in 2021.
  • Whitehawk Therapeutics' Total Current Liabilities (Yearly) stood at $30.1 million in 2020, then slumped by 49.19% to $15.3 million in 2021, then increased by 23.32% to $18.8 million in 2022, then soared by 40.14% to $26.4 million in 2023, then tumbled by 35.31% to $17.1 million in 2024.